BIO addresses data exclusivity provisions within TPP.
Share:
Press Release Summary:
In statement, BIO President and CEO Jim Greenwood said BIO is disappointed in reports from Atlanta that suggest Trade Ministers have failed to include 12 years of data exclusivity for biologics in Trans-Pacific Partnership agreement. BIO believes that 12 years of data exclusivity is a prerequisite to attract investment required to continue medical innovation and develop new biological cures and therapies. Failure of Asian-Pacific partners to agree to similar length of protection is short-sighted.
Original Press Release:
BIO Statement on Data Exclusivity Provisions Within the Trans-Pacific Partnership
WASHINGTON -- Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement today:
“We are very disappointed in reports from Atlanta that suggest Trade Ministers have failed to include 12 years of data exclusivity for biologics in the Trans-Pacific Partnership (TPP) agreement.”
BIO strongly believes that 12 years of data exclusivity is a prerequisite to attract the investment required to continue medical innovation and develop new biological cures and therapies. The current 12-year period of exclusivity in the United States was carefully crafted by a bi-partisan majority of the Congress after a thorough and thoughtful debate and deliberation. The Congress set 12 years as the appropriate period to both foster innovation and provide access to biosimilars in a reasonable timeframe. While the TPP agreement will not impact the U.S. data protection period, we believe the failure of our Asian-Pacific partners to agree to a similar length of protection is remarkably short-sighted and has the potential to chill global investment and slow development of new breakthrough treatments for suffering patients.
We will carefully review the entire TPP agreement once the final text is released by the Ministers, and will consult closely with the administration and leaders in Congress as the process moves forward.”
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Contacts
Biotechnology Industry Organization (BIO)
George Goodno, 202-439-3749
